- Home
- WLAC vs IMUX Comparison
WLAC vs IMUX Comparison
Compare WLAC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLAC | IMUX |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 152.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WLAC | IMUX |
|---|---|---|
| Price | $19.08 | $11.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $17.00 | ★ $36.00 |
| AVG Volume (30 Days) | 785.9K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $784.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.11 | $0.51 |
| 52 Week High | $21.00 | $11.76 |
Technical Indicators
Market Signals| Indicator | WLAC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 69.08 | 85.61 |
| Support Level | $11.26 | $0.75 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.61 | 0.80 |
| MACD | 0.26 | 0.63 |
| Stochastic Oscillator | 74.04 | 96.38 |
Price Performance
Historical ComparisonAbout WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.